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ABTRACT 
Curcumin is an active ingredient of Curcuma longa (Turmeric) and is studied 
extensively for its antioxidant, anti-inflammatory, anti-bacterial, anti-viral, and anti-
cancer properties.  The purpose of this study was to examine the effects of turmeric on 
blood glucose and plasma insulin levels.  The study utilized a placebo-controlled, 
randomized cross-over design with participants serving as their own control.  Eight 
glucose tolerant healthy participants completed the full study.  Three-weeks washout 
period was kept in between six-weeks. Prior to the test meal day, participants were asked 
to eat a bagel with their evening dinner.  During the day of the test meal, participants 
reported to the test site in a rested and fasted state.  Participants completed mashed potato 
meal tests with 500 mg of turmeric powder or placebo mixed in water, followed by 3 
weeks of 500 mg turmeric or placebo supplement ingestion at home.  During this visit 
blood glucose fingerpicks were obtained at fasting, 30, 60, 90, and 120 min post-meal.  
Blood plasma insulin at fasting and at 30 min after the test meal were also obtained.  
During week 4, participants reported to the test site in a rested and fasted state where 
fasting blood glucose finger pricks and blood plasma insulin were measured.  During 
week 5 to 7, participants were given a washout time-period.  During week 8, entire 
process from week 1 to 4 was repeated by interchanging the groups.  Compared to 
placebo, reduction in postprandial blood glucose and insulin response were non-
significant after ingestion of turmeric powder.  Taking turmeric for 3 weeks had no 
change in blood glucose and insulin levels.  However, taking turmeric powder 
supplements for 3 weeks, showed a 4.4% reduction in blood glucose. Change in insulin at 
ii 
 
30 min were compared with baseline insulin level showing no significant change between 
placebo and turmeric group.  Fasting insulin after 3-weeks consumption of turmeric did 
not show any significant change, but showed a larger effect size (0.08).  Future research 
is essential to examine the turmeric powder supplement benefits over a long period of 
time in healthy adults and whether it is beneficial in preventing the occurrence of type 2 
diabetes.   
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CHAPTER 1 
INTRODUCTON  
The International Diabetes Federation estimates that the number of diabetes cases 
will rise to 592 million by the year 2035 as compared to 387 million in 2015, a 53% 
increase (International Diabetes Federation,2015).  There are 4.9 million deaths annually 
due to diabetes or one death every seven seconds, one person dies from it. (International. 
Diabetes. Federation. 2015). It has shown that one of the biggest contributor to diabetes is 
the lifestyle, including diet that mainly consists of complex carbohydrate, especially high 
in glycemic index (Maki et.al. 2015). In addition, positive association has seen between 
red meat consumption and diabetes (Benedinelli et.al, 2012).  In type 2 diabetes, a 
decrease in insulin sensitivity may be due to decrease in a beta-pancreatic cells function 
causing a defect in insulin secretion (Porte et.al 2001). According to Gandhi (2014), 
diabetes is increasing in every country due to obesity and unhealthy lifestyles. However, 
it has also observed that insulin resistance can also occur in non-obese individual and aids 
in chronic diseases like cardiovascular, atherosclerotic (Hekmatdoost A, 2011).    
Curcuma longa (turmeric) is a plant root and is a member of Zingiberace family.  It is 
widely grown and consumed in India and Asian countries in the form of spice to flavor 
and give color to food. It is an ancient medicine used in Ayurveda and as a home remedy 
for cough, cold and several diseases.  It is also used as a coloring agent in the form of 
yellow-orange dye E100 in cheese, yogurt, and other food products (Esatbeyoglu T, 
2012). There is a research supporting the medicinal effect of turmeric in curing several 
diseases related to inflammation, stomach ailments and infection (Aggarwal, 2007).  Due 
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to its anti-inflammatory and antioxidant mechanism, this polyphenol has been studied in 
life-threating diseases like cancer and Alzheimer’s (Esatbeyoglu, 2012).  
C.longa has three active ingredients viz. curcuminoids, demethoxycurcumin and bis-
demethoxycucrcumin.  A number of studies have examined the active ingredient 
curcuminoids decrease in blood glucose and increase insulin sensitivity in type 2 
diabetes.  It has been suggested that curcuminoids supplementation decreases FFA’s 
(Free Fatty Acids), promoting fatty acid oxidation and utilization.  This causes glucose to 
decrease in the body (Na LX, 2012). Other studies also state that curcuminoids has an 
effect on oxidative stress by increasing antioxidant enzymes (Yang W et.al, 2015).   
Turmeric ingestion is considered safe; however, individuals with gall bladder, or 
liver diseases are advised not to ingest turmeric as a dietary supplement (NCCIH). 
Oxalate in turmeric is easily soluble in the body, and kidney stones are 80% made up of 
oxalate.  Hence, people who are prone to kidney stones or have a history of kidney stones 
are advised not to take oxalate over 50 mg a day.  It has been observed in animal studies 
that C.longa helps to lower blood glucose significantly in diabetic albino rats (N A, 
2002).  It has also been observed that when turmeric supplementation is given with an 
anti-hyperglycemic therapy like metformin, molecular complications of type 2 diabetes 
can be prevented (Salvi NM et.al, 2015).   Recent research suggests that turmeric is a 
potent inhibitor of pancreatic -amylase, a digestive enzyme that hydrolyzes starch to 
basic glucose units that are absorbed in the intestinal tract and released in the portal blood 
(Ponnusamy S, 2012).  Thus far only one study has reported directly examining the effect 
of turmeric ingestion on healthy individuals measuring postprandial blood glucose.  Due 
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to lack of proper protocol, their results did not suggest that turmeric effects in altering 
postprandial glucose in healthy adults (J Wickenberg, 2010).  The researchers have used 
Glucola as a means of high glycemia.  Thus, more study is required to see the effect of 
turmeric ingestion in healthy adults on the postprandial blood glucose.  
 
Purpose of Study 
The purpose of this experiment is to compare the effect of turmeric on 
postprandial glycemia in healthy glucose tolerant subjects following an ingestion of a 
high glycemic carbohydrate food.   
 
Research Aim  
This study will investigate the impact of 500 mg of turmeric ingestion in the form 
of dried root powder on postprandial glucose and insulin concentrations in healthy human 
subjects.   
 
Hypothesis 
Turmeric, 500 mg as a dried root powder as compared to placebo will 
significantly reduce the 2-hour postprandial glycemic response after following a test meal 
containing 80 g of starch in the form of mashed potato in healthy non-diabetic adults.    
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Definition of Terms 
▪ Acarbose®: An oral medicine used in treatment of Type 2 diabetes where it blocks 
the enzyme that digest starch in food (diabetes.org).    
▪ Alpha-glucosidase inhibitors: class of drugs used in the treatment of Type 2 
diabetes where it blocks the enzyme that digest starch in food. Migitol® and 
Acarbose® are the genetic names of the drugs used in this class (diabetes.org). 
▪ Beta-cell: a cell that makes insulin and is located at the islets of pancreas.  
▪ Bioavailability: the degree to which a substance or a drug is absorbed into the 
physiological system and is made available at the activity site.  
▪ Curcuma longa: a perennial plant belonging to Zingiberace family, where its 
rhizome is used as turmeric (Ponnusamy S, Zinjarde s, et.al. Food Chemistry, 
2012) 
▪ Fasting insulin ≥ 18 mU/mL (Mosby’s lab manual) 
o Fasting plasma glucose: 70-115 mg/dL 
▪ Glucose ranges: (Mosby’s lab manual)  
o 120 min postprandial: 70-140 mg/dL 
o 180 min postprandial: 70-115 mg/dL 
o 30 min postprandial: 110-190 mg/dL 
o 60 min postprandial: 120-190 mg/dL 
o 90 min postprandial: 95-165 mg/dL 
▪ Insulin Resistance: An impaired tissue response to the action of insulin 
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▪ Postprandial plasma glucose: the glucose area-under-the-curve for the 2-hour 
period following meal consumption 
 
Delimitations  
This study enrolled glucose tolerant healthy weight stable participants, not following a 
vegetarian diet, and are not taking turmeric supplements.   
 
Assumptions 
It was assumed that participants complied with all pre-testing diet and physical 
activity protocols:  
o consumed provided bagel with dinner meal in its entirety prior to coming 
for the meal testing  
o refrained from exercise, as well as intake of caffeine and alcohol for 24 hrs 
prior to data collection 
o appropriately fasted on the morning of the trial 
o and, consumed provided supplements for 21 days with meal  
 
Limitations 
This research is limited by participant adherence to protocol.  Sample size may 
have limited the data interpretations.  Turmeric dosage of 500 mg may also have played a 
role in the study limitation.  
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CHAPTER 2 
REVIEW OF LIETERATURE  
History of Curcuma Longa (turmeric) 
Curcuma longa (turmeric) is a plant that is mostly grown in Asia, India and 
China. It is a plant root that belongs to the ginger family Zingiberaceae.  In the 13th 
century, Arabian merchants brought turmeric to the European market from India, where it 
got the name “Indian saffron” (Aggarwal 2007).  During 15th century it was combined 
with other spices to form curry powder.   The plant grows in a hot, humid climate and it 
requires a large quantity of water.  It grows up to one-meter-long, has oblong, tufted 
leaves and produces 6-10 tubers (Wickenburg 2010). The tubers are dried and then 
grounded to get the golden-yellow turmeric powder.    
 
Turmeric and Its Components 
 Turmeric has main three components: Curcuminoids, dethoxycurcumin and 
bisdemethoxycurcumin.  Curcuminoids contain curcumin and is known to have the 
highest bioactive component that consists of 3 to 5% in a turmeric root.  It is very rare to 
find pure curcumin, however it is possible to get the three main components of turmeric 
from the mixture of turmeric power by following crystallization and column 
chromatography method (Osorio-Tobon JF 2016).  Due to curcuminoids in rhizome, 
turmeric gets its golden-yellow color.  Turmeric contains 1-5% of an essential oil that is 
used in aromatherapy (Estabeyoglu 2012).  Curcumin is insoluble in water and has a 
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lipophilic property (Jurenka J 2009).  It is most stable from 1.0 pH to 6.0 pH, found 
mostly in the stomach and intestine. (Shashikumar 2005).   
 
Turmeric Uses 
Turmeric is primarily used as a spice in Indian and Asian cuisine that gives food a 
distinct flavor and golden color.  It has been used in Ayurvedic medicine as well as other 
eastern medicines for at least 2500 years (Gupta 2013).  Its medicinal properties have 
been used for inflammatory disorders, arthritis, stomach ailments, sores, infections, 
cough, cold, acne, and burn etc. (Ghorbani 2014).  There has been no reliable data to 
support these medicinal usages of turmeric due to few clinical trials (NCCIH 2012). 
Turmeric is also used to make color.  It makes the orange-yellow dye E100 to use in 
cheese, butter, mustard, dairy products and canned fish (NCCIH 2012).   Due to its bitter 
taste and piquant earthy scent it is not used to season desserts and cakes (Estabeyoglu 
2012).   
 
Bioavailability  
The bioavailability of curcumin is primarily dependent on the metabolism within 
the body, especially in intestine and liver.  Oral bioavailability of curcumin is low in the 
body due to less small intestine absorption.  This has been seen in a study done on rats, 
where 1 g/kg body weight of curcumin was given orally and most of it got excreted 
through feces. (Suresh 2010, Ravindranath 1980, Estabeyoglu 2012, Shoba 1998).   
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Additionally, the liver has a very high bioavailability.  Only high doses of curcumin in 
plasma is bioavailable and it has been observed within the first two hours of ingestion.  
Curcumin is metabolized by Phase I and II enzymes like cytochrome P450 
monooxygenase, alcohol dehydrogenase, methyltransferase, acetyl co-enzyme A etc.  It 
has been noted that curcumin inhibits phase I metabolism while it stimulates phase II 
metabolism.  In phase II metabolism of curcumin, they are conjugated with glucuronic 
acid and sulfate present in enterocytes and hepatocytes (Hoehle 2007).  These curcumin 
conjugates exit the enterocytes with the help of multidrug resistance-related proteins 
(MRP) namely MRP1 and MRP2 respectively.  These are under the influence of 
transcriptional factor known as nuclear factor 2 (Nrf2) that gets turned on by curcumin 
(Estabeyoglu 2012).  This shows that curcumin has a poor bioavailability in the body and 
is exerted easily once ingested.     
It is known that curcumin is lipophilic and insoluble in water.  Hence, in order to 
increase the bioavailability, research has shown that when curcumin is taken with 
piperine it can increase the bioavailability by two folds.  Peperine is a molecule present in 
pepper vine, piper nigrum, hot jalapeno, peppers and peppercorns (Sharma RA, 2005).  In 
one study, when humans were given 2 grams of curcumin along with 5 grams of 
peperine, it showed that in two hours, the bioavailability increased by two fold when 
compared with only curcumin consumption subjects (Arcaro 2014). In another study by 
Shoba and colleagues when 2 g of curcumin was administered with 20 mg of pepper 
constituent in fasting individuals it was observed that bioavailability of curcumin 
increased by 2000% (Shoba G, et al., 1998).  It has been understood by the researchers 
 9 
 
that in the presence of piperine, glucouronidation of curcumin gets inhibited.  Thus, there 
is no Phase II metabolism of curcumin where it can no longer go through conjugation 
reactions.  In the presence of piperine, curcumin cannot further convert into a polar, water 
soluble form and it cannot excrete through renal system (Srinivasan 2010).  Hence, 
piperine can help in increasing curcumin bioavailability.   
 
Safety of Turmeric  
Turmeric has been considered safe for use in the form of spice for centuries.  As 
of now, there has been no data registered regarding the toxic effects of turmeric in a 
general population.  (NCCIH 2012, Lao et.al 2006).  The U.S. Food and Drug 
Administration (FDA) has accepted turmeric as a safe ingredient even in high doses.  
However, Tang (2008) finds that due to the presence of oxalates in turmeric, people who 
have history of kidney stones or are at high risk of developing one, should not take 
turmeric.  The study was a randomized crossover where six subjects were signed for 3.0 g 
of cinnamon treatment and 5.0 grams for turmeric treatment for a four weeks’ period.  
Subjects were required to take the respective two supplements three times a day.  
Subjects were given breakfast containing low calcium and less oxalate.  Oxalate, creatine 
and calcium content were measured from 6 and 22-hour urine analysis. It was noted that 
turmeric had a high oxalate content of 91% and cinnamon had only 6%.  This shows that 
consumption of turmeric can significantly increase urinary oxalate levels and can 
increase the risk of kidney stone formation.     
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Turmeric and Scientific Research 
Turmeric has been one of the most studied herbs in the modern world.  The 
interest has increased in studying this herbal plant especially due to its therapeutic 
importance.  In addition, current research trend shows that there is an increase in 
polyphenol studies due to their protective roles against various chronic diseases like 
cardiovascular and cancer.  Curcumin is the most active component of turmeric.   Despite 
its traditional use, several studies mainly in pharmacology have measured its medicinal 
properties like antioxidant, anti-inflammatory, anti-bacterial, anti-tumor etc. Curcumin 
has these multiple effects due to it polyphenol property and can modulate several 
physiological pathways (Gupta 2013).  It is understood that there are several researchers 
sited related to the turmeric’s active ingredients and compounds.   
In vivo, it has shown that curcumin, an active ingredient of turmeric decreases the 
activation of human dendritic cells when inflammatory cytokines are activated 
(Karsovsky 2009).   This shows that turmeric extracts have an anti-inflammatory effect.   
Besides this, turmeric has a positive effect on myocardium injury.  In a study, when 
Wistar albino rats were fed 100 mg per kg turmeric daily for one month, anti-apoptotic 
activity was noticed showing a cardio protection of turmeric.  This increased the 
functional recovery period related to cell necrosis (Mohanty et. al 2006).   
Several studies have described anti-carcinogenic and chemo protective effects of 
curcumin.  These preventive effects of curcumin are directly or indirectly regulated by 
signal transduction pathway.  Tumor suppressor gene p53 has been known for important 
cell growth and apoptosis.  When the cells in the body get dysregulated, p53 pathway in 
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the presence of curcumin takes over and helps in DNA-binding activity leading it to 
apoptosis of the cell.  Curcumin can also lower the p53 gene expression in non-malignant 
cells. Thus, curcumin can prompt cancer killing cells with the p53 pathway and act as a 
chemo protective agent (Sa 2008).    
Curcumin consists of antioxidant, anti-inflammatory and lipophilic properties.  
Due to the presence of these properties and observing an association between turmeric 
consumption and lower incidence of Alzheimer’s disease in Indian and Asian population 
by 4.4 times, there is a growing evidence that curcumin consumption can help in 
Alzheimer disease including dementia (Ganguli M et al., 2000).  In a study, association of 
turmeric powder in the form of curry in 1010 Asians, aged between 60 and 93 years was 
investigated.  It was noted that individuals who ate curry more than once a month had 
better perform cognitive test than who ate curry less than a month (Ng TP., 2006).  
According to World Health Organization (WHO), 5% men and 6% women above the age  
of 60 years are affected with Alzheimer’s type dementia worldwide (Fratiglioni L., et al, 
1999).   In pathogenesis of Alzheimer’s disease there is a chronic inflammation of nerve 
cells. Due to anti-oxidant property present in curcumin, it binds to certain proteins in 
monocytes and suppress gene factor (Erg-1) and reduces inflammation (Pendurthi UR, 
Rao LV., 2000).  It has also understood that in the presence of curcumin, pro- 
inflammatory cytokines (IL-1, IL-6, and TNF) production is inhibited (Mishra S. et al., 
2008).  This suggests that, curcumin works as a potent inhibitor of pro-inflammatory and 
cytokine production.  Curcumin’s antioxidant property was studied on rats and it was 
observed that when curcumin is administered, lipid peroxidation and lipofuscin levels, 
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products of brain damage decreased significantly (Bala K et al., 2006).  It has also been 
studied that in Alzheimer’s disease there is a huge accumulation of plaques known as 
beta-amyloid plaques (Mishra S.et al.,2008).  In vitro, when these plaques present in 
macrophages were treated with curcumin it was observed that the plaques decreased 
significantly (Zhang L., et al.,2006).  This suggests that curcumin has a beneficiary effect 
in Alzheimer’s disease.   
Turmeric when taken as a dietary supplement can increase the pancreatic lipase 
chymotrypsin along with amylase activity. In addition, when turmeric is mixed with other 
spices like black pepper and cumin it has shown an increase in bile flow and secretion 
(Plate 2002). Thus, turmeric can act as a digestive stimulant.  
Concurrently, turmeric has been studied in humans to see the counter effect 
against several diseases.  Bundy and colleagues (2004) studied the effects of turmeric on 
irritable bowel syndrome in randomized partially blinded pilot study in 207 volunteers.  It 
was observed among volunteers that 53% reported their bowel changed when they took 
72 mg of one tablet daily and 60% reported with their bowel changed after taking 2 tablet 
daily.  In addition, it was noted that there was a decrease in volunteer’s abdominal pain 
and discomfort levels by 22% and 25% in the one- and two-tablet groups respectively 
(Boudy R, Walker AF, Middelton RW, Booth J., 2004).  Hence, turmeric may help in 
reducing irritable bowel syndrome symptomology.    
Turmeric supplementation has shown a healing effect in peptic ulcers.  
Prucksunand and colleges (2001) did a clinical trial study where 45 patients with peptic 
ulcer received 300 mg, 2 turmeric capsules, five times a day.  After four weeks of the 
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treatment it was noted that peptic ulcer was cured by 48% in the patients, which further 
increased to 76% at the end of 12th week.  Besides this, Shimouchi et al. (2009) studied in 
eight healthy subjects that 500 mg of turmeric taken in the form of curry with rice 
increases hydrogen producing bacterial flora in colon and bowel motility after 12 hours 
of fasting.  This shows that dietary turmeric can activate bowel motility along with 
carbohydrate colonic fermentation.  
Besides turmeric supplementation, turmeric oil has also been studied in various 
conditions.  Honda et al. analyzed the hepatic gene expression in mice when turmeric oil 
containing 14% by weight curcuminoids (6.5% curcumin, 2.3% demethoxycurcumin and 
1.9% bisdemethoxycurcumin) was ingested in obese diabetic mouse for one week.  This 
study was done by using DNA microarray analysis, a polymerase chain reaction (PCR) 
by comparing different oils.  It was observed that turmeric oil inhibited the increase of 
blood glucose levels in the diabetic mice along with abdominal fat (Honda S, Aoki F., 
Tanaka H et al., 2006).  
 
Turmeric and Glucose Metabolism  
 Several studies have examined the effects of curcumin in blood glucose levels.  A 
study conducted by Arun N and Nalini N (2002) measured the efficacy of turmeric on 
blood sugar in diabetic albino rats.  During the study, diabetic albino rats were 
administered with 80 mg/kg with curcumin for 21 days.  This showed a significant 
decrease in blood sugar, hemoglobin, and glycosylated hemoglobin.  Further analysis 
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showed that curcumin also decreased the sorbitol dehydrogenase enzyme activity that 
further converts sorbitol to fructose.  In another study it was shown that when 10, 20 and 
30 mg/kg body weight of turmeric extract was given orally to streptozotocin (STZ) 
induced rats for 42 days, it showed a decrease in blood glucose levels.  The best results of 
decreased blood glucose were measured when turmeric was administered at 30 mg/kg 
body weight.     
 Anti-glycemic effects have also been examined in rats.  In a research study done 
by Weisberg SP et al. 2008, obese male rats and diet induced male rats have been studied.  
After two weeks of the treatment, 3% dietary curcumin decreased the blood glucose 
levels.  It also showed decrease in the 2-hour glucose tolerance test results where 3% by 
weight of curcumin was given along with 4% fat by weigh or high fat diet containing 
35% fat for two weeks.  This also shows that curcumin decreased the HbA1c levels in 
both diet induced mice as well as obese mice after 5 weeks of curcumin treatment.   In 
addition, insulin resistance was also measured in this study, where both the types of rats 
were kept in a cage for 6 hours and every fifteen minutes, blood glucose levels were 
measured for a total of 2 hours.  The results showed a decrease in area under the curve of 
the obese male rats’ percent basal glucose.   
 The effects of curcumin on glycemia in diabetic models of rats and mice have be 
explained by El-Azab his study.  When 10 mM curcumin was injected for 28 days it 
decreased the tumor necrosis factor-α (TNF-α) levels along with IL-1B (pancreatic islets) 
due to its anti-inflammatory properties.  In another study it was noticed that plasma TNF-
α level and free fatty acid levels, were directly correlated to obesity-related insulin 
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resistance and T2DM. Thus, when curcumin was fed in rats, it improved the glucose 
tolerance when compared with the untreated rats.  (El-Moselhy MA 2007).  In addition, 
curcumin also can elevate plasma insulin levels and increase lipoprotein lipase (LPL) 
activity (Sea I-K 2008).  This was observed in a study to measure the effect of curcumin 
when male diabetic mice where fed curcumin for six weeks and then compared to non-
diabetic male mice.  The results showed that there was an increase in insulin resistance 
and glucose tolerance along with high insulin levels in diabetic mice who consumed 
curcumin 0.02% weight per body weight.  Hence, it illustrates that curcumin increases the 
enzyme activity in liver that process glycolysis along with glycolysis and 
gluconeogenesis (Sea KI et al. 2008).     
 Interestingly, turmeric has been studied with other substances to see the combined 
effect in the glucose levels. Patumraj S. and colleagues (2006) studied the combined 
effect of vitamin C and curcumin in hyperglycemic Wister Furth rats with 
hyperlipidemia.  These streptozotocin induced rates were given 300 mg/kg body weight 
of curcumin along with 1 g/l of ascorbic acid mixed in drinking water for seven weeks.  It 
was observed that blood glucose, lipid profiles, glycosylated hemoglobin were 
significantly decreased when compared to the control group of diabetic rats.  Hence, this 
suggests that curcumin can enhance ascorbic acid metabolism in the body by protecting 
the endotheila cells due to its anti-oxidant property (Patumraj S., Wongeakin N., 
Sridulyakul P., Futrakul N., Bunnag S., 2006).     
Gultierres and colleagues (2012) examined the prolong effects of forty-eight 
diabetic rats to understand the changes that occurred with curcumin-supplementation 
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mixed in yogurt.  Curcumin was mixed in the yogurt with different dose levels of 30, 60 
and 90 mg/kg body weight per day.  These various sample doses were given to diabetic 
rats and were compared with non-diabetic rats for 31 days.  It was observed from the 
blood samples that rats who ate 90mg/kg body weight a day of curcumin mixed with 
yogurt decreased their glucose levels by 10 mmol/l and were noted to be steady at that 
rate.  However, rats in control group showed no decrease in blood glucose levels.  
Additionally, urine samples were also collected and at the seventh day of the study, 
where rats with curcumin and yogurt showed a decrease in urine glucose levels when 
compared to the first day of urine samples.  This fall in glycemia is furthermore explained 
by studying the pancreatic islets that curcumin could have stimulated the secretion of 
insulin in the body.  Thus, this study suggests that the β-cells that got destroyed due to 
the fall of insulin levels in the body was due to curcumin probably altering the enzyme 
action and this could have helped in bringing glucose levels to a normal level.   
 It has been understood that in the presence of oxidative stress due to 
hyperglycemia, β cells generation slows down. A study was done in human pancreatic 
islets at a cellular level to see the effects of curcumin and its analogs on the induction of 
antioxidant enzymes in the β-cells of pancreas.  With the help of double 
immunofluorescent staining techniques, islets were induced with curcumin and its 
different analogs in β-cells.  This showed that there was an increase in the antioxidant 
enzymes like heme oxygenase at the cellular level in particular with the m-RNA and 
protein levels.  Modularly sub-unit of gamma-glutamyl-cysteine ligase, a content of 
glutathione was increased along with basal insulin secretion.  Thus, this cellular 
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mechanism of curcumin can suggest that it can help protect pancreatic islets from getting 
damaged due to oxidative stress.  (Balamurugan 2009).         
 Furthermore, other analogs of curcumin have also showed antidiabetic properties.  
Bis-o-hydroxycinnamoylmethane, a natural curcuminoids of BDMC has been studied in 
diabetic rats and have shown positive results by increasing antioxidant defense system.  
(Srinivasan 2003).  0.05, 0.1, and 0.2 mmol/kg/day per body of bis (curcumino) 
oxovandaium has also shown a decrease in blood glucose levels in diabetic rats 
(Majithiya 2005).   
 In addition to decreased glucose absorption rate, curcumin has also been studied 
and shown to increase GLUT 4, GLUT2 and GLUT 3 gene expression.  GLUT 2 and 
GLUT 3 are facilitated glucose transporters that carriers’ glucoses across cell membranes 
and GLUT 4 is located on the cell membrane of muscle cells and adipocytes and is relied 
on insulin (Jellinger 2007).  Insulin receptors bind to the adipocyte and muscle cell 
receptor creating a cascade that leads to GLUT-4 to plasma membrane.  This creates an 
influx of glucose in the presence of insulin.  On the contrary, when insulin is absent 
GLUT-4 in cytosol is surrounded by membrane vesicles.   
In a study done by Peeyush et al. (2009), it was observed that curcumin can help 
mediate other neuroprotective roles in the presence of hyperglycemia.  When 60 mg/kg 
curcumin was fed for 14 days to diabetic induced Wistar rats, GLUT 3 with gene 
expression of acetylcholine esterase, an enzyme that functions as neurotransmitters was 
observed.  It was seen that the esterase enzyme increased GLUT 3, Muscarinic M1, M3, 
7 nicotinic acetylcholine and insulin receptors in the cerebellum of diabetic rats. This 
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was noted when the insulin along with curcumin inhibited the enzyme action of 
acetylcholine esterase, GLUT 3, insulin and receptors.  This shows that curcumin 
regulates the activity of cholinergic and insulin receptors respectively.  Thus, this study 
shows that curcumin has a therapeutic role for protection along with prevention of 
aggressive diabetic complications (Peeyush KT., Gireesh G, Jobin M, Paulose CS., 
2009).   
Pugazhenthi and colleagues showed that the if further purification of curcumin 
and other analogy like demethoxycurcumin (DMC), and bisdemethoxycurcumin 
(BDMC) is done, then the expression of heme oxygenase-1 expression (HO-1) through 
PI3K/Akt signaling of β-cells in mice is regulated.  Real-time reverse transcription 
polymerase chain reaction also showed that DMC and BDMC increased the levels of 
glutamyl cysteine ligase enzyme with the synthesis of glutathione and NADPH 
(Pugazhenthi S, Akhov L., Selvaraj G., Wang M, Alam J., 2007).   
 
Turmeric in Human Studies 
 Turmeric has been seen to give a favorable effect on decreasing inflammatory 
cytokines and markers of oxidative stress in type 2 diabetes mellitus patients when 
compared with atorvastatin and placebo treatments.  It is known that one of the clinical 
signs of atherosclerosis is the vascular complications and endothelial dysfunction.  In the 
study conducted by Ushrani and colleagues, a formulated curcuminoids two capsules of 
150 mg were given twice daily for 8 weeks.  This was compared with the group of 
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participants who were taking 10 mg of atorvastatin, cholesterol-lowering medication and 
placebo one capsule twice daily.  It was noted that curcuminoids formulated drug had a 
beneficial effect on endothelial functions along with decrease in inflammatory cytokines 
and malondialdehyde, however, total cholesterol and triglycerides did not change. As it is 
known from previous studies, atorvastatin significantly improved and decreased all of the 
factors including total cholesterol and triglycerides in type 2 diabetic patients.  Thus, 
curcuminoids can have a beneficial role in protecting patients with high levels of 
cardiovascular risks by improving endothelia function (Usharani P, Mateen A, Naidu 
MU, Raju YS, Chandra N).    
 Na LX and colleagues studied the effect of curcuminoids for three months in 100 
obese type 2 diabetic patients.  300 mg per day of curcuminoids supplements were given 
to the patients for 3 months.  It was observed that patients taking 300 mg per day of 
curcuminoids, fasting blood glucose and insulin resistance index (Homeostasis Model 
Assessment of Insulin Resistance -HOMA-IR) reduced significantly along with HbA1c 
and free fatty acids (FFAs).  This reduction is speculated due to decrease in FFAs which 
may result from promoting fatty acid oxidation and utilization (Na LX et al., 2012).   
 
Proposed Mechanism   
It has been observed that the principle bioactive component in curcumin is 
responsible for the inhibition of pancreatic -amylase enzyme.  It is known that alpha-
amylase hydrolyses starch and glycogen.  Now, when the enzyme gets inhibited by 
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curcumin, it slows down the carbohydrate metabolism into simple sugars.  Hence, the 
blood glucose levels do not rise.  Ponnusamy and colleagues have reported this 
mechanism by analyzing bisdemethoxycurcumin kinetic effects.  Bisdemethoxycurcumin 
is one of three main components of turmeric. Bisdemethoxycurcumin acts a potent small 
molecule inhibitor for human pancreatic -amylase.  This analysis was done in a series of 
bioassay-guided purification steps.  At every step, column fraction was assayed for -
amylase inhibition and active fraction were taken further.  At the end, three curcuminoids 
were formed.  One of the curcuminoids was dimethoxycurcumin and other two were 
bisdemethoxycurcumin (Ponnusamy 2012) and were analyzed for human pancreatic 
amylase, where inhibition was observed in the presence of bisdemethoxycurcumin 
(Ponnusamy S, Zinjarde S, Bhargava S, Rajamohoanan PR, Ravikumar A, 2012).   
Turmeric is shown to increase the pancreas secretion of insulin.  Fourteen healthy 
human beings were recruited for this cross over study in Sweden. (Wickenberg J et al. 
2010).  Subjects who have thyroid disorders and diabetes mellitus were excluded from 
the study.  Each subject’s fasting glucose was measured after a 12 hour fast.  Oral glucose 
tolerance test was used to measure the postprandial plasma glucose response and 
postprandial insulin response.  Subjects were given a total of fifteen 400 mg of turmeric 
with 170 mg of lactose supplements or just 560 mg of lactose supplements as a treatment 
and placebo plan for a week long study.  Insulin concentrations were measured at 0 min 
and at 1 hour.  This showed that total of 6 grams of turmeric increased the insulin 
response in the blood stream.  The highest peak of insulin was noted at 30th minute.  
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Compared to the placebo group, turmeric group maintained the increase of insulin in the 
blood for the entire 120 minutes.   
 
Turmeric and Pharmaceuticals 
Curcumin has been studied prevalently in the pharmaceutical world.  Drug 
mechanism of certain drugs used for anti-depressant, anti-coagulant has shown very 
similar effect with curcumin ingestion.  In a study conducted by Bhutani and colleagues 
(2009) anti-depressant like effect of curcumins with combination of piperine were 
observed.  When 20 and 40 mg of curcumin per kg was given to female Wistar rats for 21 
days along with 2.5 mg per kg of piperine, it was observed that there was an increase in 
monoamine oxidase (MAO) enzyme activity.  In addition, it increased serotonin and 
dopamine concentrations in the body.  This suggests that curcumin exerted 
antidepressant-like effect in chronic unpredictable stress induced depressed rate models 
((Bhutani MK, Bishnoi M, Kulkarni SK., 2009).  In vivo anticoagulant activities of 
curcumin and its constituents have been studied.  Study data suggests that curcumin and 
increased the Partial Thromboplastin Time (PTT) significantly.  It also showed the 
inhibition of thrombin activities.  Hence, this shows that curcumin has an anticoagulant 
activity (Kim DC, et al. 2012).  In another study when curcumin containing 5 and 10% 
ethanoic extract ointment was given to wounded rats it was observed that there was a 
significant difference with remarkable healing process against the wounds.  This was 
compared against retardation of wound healing process by 150 mg per kg of aspirin.  This 
is understood due to increase in cellular proliferation and collagen synthesis at the wound 
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when curcumin ointment is applied.  This shows that curcumin has capacity to enhance 
wound to heal (Pawar RS, Toppo FA, Mandloi AS, Shaikh S., 2015).   
 
Type 2 Diabetes Mellitus  
 Type 2 diabetes mellitus is a disease that causes sugar levels to go high in blood 
stream due to body’s inability to absorb the sugar and use the insulin, a hormone 
produced by pancreas.  Initially, pancreas tries to compensate the increase in sugar levels 
in body by producing more insulin but gradually it gets detreated and sugar levels 
increases.  Over time, these high amounts of sugar in the blood produce an adverse effect 
on the body by slowing the circulatory systems and damaging different organs of the 
body like heart, kidney, nerves, eyes etc.  According to the International Diabetes 
Federation, by the year 2035 there will be a high rise in the diabetes cases.  They have 
predicted that the number will rise from 387 million to 592 million, a 53% increase.  
Annually, 4.9 million deaths have been recorded due to diabetes.   
 
Treatment in Type 2 Diabetes  
 Absence of insulin due to defect in the pancreatic cells or increase in insulin 
values due to body’s inability to respond to it in the presence of sugar in the blood, 
become insulin resistance over time.  This occurrence could be due to uncontrollable 
function of their liver making insulin.  In some conditions, if the insulin cells are 
damaged they send out wrong information about blood sugar and blood sugar level rises.  
If diabetes is not diagnosed over time, long term effects like damage of kidneys, blood 
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vessels, heart, eyes, nerve damage etc. occurs.  Hence, it is essential to monitor and 
manage diabetes to avoid further complications.  
 Over the time, science has been a boon in treating type 2 diabetes with new 
medicinal innovations and discoveries.  There are now several medications and injections 
available to control blood glucose and insulin levels in the body.  There are more than 20 
types of insulin sold in the United States, where each insulin follows a different 
mechanism that it works in the body.  Rapid-acting, short-acting and intermediate-acting 
and long-acting are the four main types of insulin.  These insulins start working in the 
body from as little as 5 minutes and it can be effective in the body for 12 to 18 hours and 
some even 24 hours.  NovLog®, Levemir®, Lantus® etc. are the common insulin 
injections available for diabetic patients.  There are six classes of oral medicines and 12 
individual drugs available in the United States to control type 2 diabetic patients blood 
sugar levels.  Metformin® is the most common drug that is used for more than a decade.  
It is from a class called the sulfonylureas that is used in the management of type 2 DM.  
Metformin® works by suppressing endogenous glucose production and increasing muscle 
and fat cell sensitivity for the action of insulin in liver.  It reduces insulin resistance and 
improves glycemic control (Papanas N., Mikhailidis DP., 2009).  In addition, metformin 
has also shown to work favorably on blood pressure, lipids, hemostasis along with 
improving cardiovascular disease in type 2 diabetes patients (Papanas N., Mikhailidis 
DP., 2009, Despres JP.,2003).    This medication has been recommended by American 
Diabetes Association (ADA) due to its less side effects like weight gain, hypoglycemic 
attacks and also blood glucose lowering effect (Hiroyuki Ito et al.,2010).  Initially, it was 
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used to treat obese type II patients (Bell PM, 1997). However, over the course of time, 
this class of medication works on both, obese and non-obese patients.  In a study done on 
213 patients with type 2 diabetes it was observed that with the long-term treatment of 
metformin therapy in non-obese patients gives a beneficial effect.  When the effect was 
compared it was similar to obese patients.  HbA1c levels were noted equal between the 
non-obese and obese groups.  In 12 months, HbA1c was reduced by 1.2% in non-obese 
and by 1.1% in obese patients.  Hence, even though the dosage is not similar in two 
groups, the effect of the drug on the individuals were noted similar when comparing there 
HbA1c levels (Hiroyuki et al., 2010).  Donnelly et al. has reported that metformin is more 
effective in type 2 diabetic patients with a lower BMI, however with a small clinical 
impact as the reduction of HbA1c in non-obese patients of 1.46%, was similar to that of 
obese patients, 1.34%.  Hence, this shows that glycemic response to metformin in non-
obese and obese patients is similar (Donnelly LA., 2005).   
 Unlike other pharmacological therapies for type 2 diabetes mellitus (insulin and 
sulfonylureas), long term consumption of metformin does not lead to weight gain in type 
2 diabetic patients. This was observed and analyzed by The diabetes prevention program 
research group in a 7-8 year follow up in a 2,155 patients taking metformin in a 
randomized double-blind clinical trial versus placebo. This study took place from 27 
various clinics across states.  Patients took 850 mg per day of metformin or placebo and 
then was increased to twice a day.  Weight was measured twice every year along with 
waist circumference, and hematocrit and hemoglobin measured annually.  Over the 
course of time, it was observed that patients who took metformin, their hemoglobin and 
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hematocrit slightly decreased.  Above all it was noted that patients who took metformin 
had reduced body weight and waist circumference compared to placebo.  Thus this shows 
that over the course of time, metformin helps in weight loss once it is adhere by the 
patient (Diabetes Care, 2012).   
 Another class of oral glucose-lowering drug used in the treatment as well 
prevention of type 2 diabetes mellitus is α-glucosidase inhibitors (AGIs).  This class of 
drug works by altering the intestinal absorption of carbohydrates, enzymes found in the 
brush border of gut epithelium, into simple sugars to monosaccharides.  This is easily 
absorbed in the intestine and it decreases the bioavailability of carbohydrates in the body 
(DiNicolantonio JJ, 2015).  This effect of AGIs helps in reducing postprandial 
hyperglycemia (Deros G, Maffioli P.,2012).  The three common AGIs used in clinical 
practice are Arcobose®, Voglibose®, and Miglitol®.  It has been studied that AGIs, 
particularly Arcobose may be safe and effective for the treatment of prediabetes and 
diabetes (Deros G, Maffioli P., 2012).  
 In order to observe AGIs impaired glucose tolerance, Kawamori et al. conducted a 
study to understand Voglibose® in the prevention of developing type 2 diabetes.  It was 
noted from this study that patients who were on Voglibose®, had significantly lower risk 
for progression of type 2 diabetes than placebo along with showing normoglycemia in the 
treatment group. In the study STOP -noninsulin-dependent diabetes mellitys (STOP – 
NIDDM) study it showed that Arcobose® reduced the risk of developing diabetes by 49% 
(Chiasson et al.2002).  Hence, AGIs can help in decreasing the progression of type 2 
diabetes along with reducing HbA1c, fasting blood glucose.       
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Herbs Used in Type 2 Diabetes Mellitus  
 Prevention of hyperglycemia due to insulin deficiency or insulin resistance has 
been the motto from ages.  Besides allopathic medications, natural alternatives have 
always been in search to prevent and cure type 2 diabetes.  Discovering new antidiabetic 
agents and finding active ingredients and compounds from herbal plants have been 
studied since ancient times like in Ayurveda and Unani, ancient Indian system of 
medicine.  Herbs prepared by boiling, extracting juices, fermenting juices and powders 
have been used in the form of treatment for type 2 diabetes.  It is known that a single herb 
exerts has several different actions on different diseases (Sexena, 2004).  Besides, it can 
also have a synergistic and adversary effects in combination with other herbs (Pendse and 
Iyengar, 1961, Sexena, 2004).  There are few herbs that have been proved scientifically to 
show positive outcome in the treatment of diabetes.  Bitter melon, Fenugreek, Tinospora, 
and pomegranate are some of the herbal plants and trees that have shown positive results 
in treating diabetes.   
 Bitter melon belongs to the Cucurbitaceae family and is grown in tropical areas in 
India, Asia and South America (Sexana, 2004).  Its juice has been used as a 
hypoglycemic agent in Indian ancient medicine (Sharma, 1996, Sexana, 2004).  It was 
observed in vitro that bitter melon juice has an inhibitory effect on glucose absorption in 
the intestine (Meir and Yaniv, 1985, Sexana, 2004).  Higashino et al. observed that it also 
enhances insulin release from beta cells (Higashino et al., 1992).  In addition, Welihinda 
et al.  also noted that bitter melon increases glucose uptake by tissue and has an extra 
pancreatic effects by increasing beta cells that helps in regulating blood glucose levels 
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(Welihinda et al., 1998).  It has been studied that phytochemicals of bitter melon have 
insulin mimetic activity.  Murthy et al. (2002) studied the phytochemical compounds and 
found that when 400, 300, and 100 mg/kg per day doses were ingested in mildly diabetic 
rabbits, hypoglycemic effect was observed in them.  This effect is speculated due to their 
galactose-binding lectin, insulin-like protein present in them (Ng et al,.1986, Sexana, 
2004).  In the study conducted on eight-insulin dependent participants it was observed 
that when 4 g of bitter melon powder was ingested for 21 days, postprandial blood 
glucose level was decreased significantly (Habib A., 2003).   
 Fenugreek is another herb plant, in the Leguminoseae family that has been used in 
type 2 diabetic treatment.  It is a native to western Asia and southeastern Europe and is 
cultivated in Mediterranean region, China, and northern India (Saxena A.,2004).  Studies 
on rats have shown diminution in fasting blood glucose by approximately 80% (Saxena 
A.,2004).  Khosla and colleagues studied the effect of 2 and 8g/kg of fenugreek dose in 
diabetic rats.  It was observed that the blood glucose levels were decreased significantly.  
Interestingly, in this study normal non-diabetic rats blood glucose was also decreased at a 
given dose (Khosal P. Gupta DD, Nagpal RK).  This shows that ingestion of fenugreek 
may be beneficial in controlling blood glucose levels in normal as well diabetic 
individuals.  In a double blind placebo controlled study conducted with 25 mild type 2 
diabetic patients showed an improved glycemic control and decrease insulin resistance.  
In this study 1 g/day extract of fenugreek seed (hydroalchoholic extract) were given to 12 
patients and were compared with 13 other patients who received placebo capsules.  When 
results were measured after 2 months, it was observed that consumption of fenugreek for 
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2 months have decreased the insulin significantly (Gupta A., Gupta R., Lal B.,2001).  
Hence, this shows that when fenugreek is taken in type 2 diabetes as an adjunct therapy it 
can help in improving glycemic control and decreasing insulin resistance. 
 Tinospora is a member of the Menispermaceae family and is grown in India, 
Myannmar and Sri Lanka (Saxena, 2004).  Traditionally its juice has been used in 
diabetic patients.  In the study done on albino rats, ingestion of 2.5g/kg and 5.0 g/kg dose 
of root extract, showed decrease in fasting blood glucose. (Stanely et al.,2000) The 
reduction was noted of approximately 130mg% after the supplementation.  It has been 
noted from different studies that tinospora root extract decreases the levels of 
ceruloplasmin, alpha-tocopherol in diabetic rats along with increasing Vitamin-C 
concentrations which acts as an inhibitors of free-radical-mediated lipid peroxidation 
(Prince et al.,1999. Meistor and Anderson, 1983, Saxena, 2004).   
 Pomegranate is a fruit filled with rich-red colored juicy seeds.  It is a small tree 
that is from the Lythraceae family originated in Asia and is widespread in Mediterranean 
regions, South Africa and China (Saxena, 2004).  Flower, seeds, rind are this plant’s part 
that are known to have an antidiabetic effects.  In the study conducted on diabetic rats, it 
was observed that when seed extract doses of 300 mg/kg and 600 mg/kg were given, 
blood glucose levels were reduced by 47% and 52% respectively within 12 hours (Das et 
al.,2001).  When flower extract was administered to a normal, glucose-fed and 
streptozotocin-induced diabetic rats, it was found that the extract of 400 mg/kg decreased 
blood glucose level effectively.  However, the mechanism is yet unclear with a 
speculation that it may increase peripheral glucose utilization (Jafri et al.,2000, Saxena, 
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2004).  Sharma et al., (1983) also suggest the mechanism that may inhibit proximal 
tubular reabsorption for glucose in kidney. (Sharma et al.,1983, Saxena, 2004).   
 Herbs and plants have shown to have many health beneficial properties especially 
the one discussed above in controlling blood glucose levels in the body.  This herbs 
exhibit hypoglycemic, hypolipidemic and antioxidant properties in animals and humans.  
However, these observations are on few studies and mostly on animals.  Thus, more 
detailed study should be conducted on these herbs to evaluate the exact mechanisms that 
each one works on the body as there may be several active ingredients present in them.   
Cinnamon is a bark, that is obtained from several tress belonging to the family of 
Lauraceae (Iqbal, Mohammad, 1993).  It is used as flavoring spice.  Studies have shown 
that consumption of cinnamon spice helps in controlling fasting blood glucose in type 2 
diabetic patients.  Study conducted by Khan et al. (2003) showed that when 1, 3 or 6 g 
per day of cinnamon was added in 60 type 2 diabetic patients diet for 40 days, their 
fasting blood glucose decreased.  The reduction of fasting blood glucose was the most 
statistically significant for the dose of 6 g per day of cinnamon ingestion.  In a review 
article of clinical trials Allen et al. concluded that cinnamon is associated with a 
statistically significant decrease in fasting blood sugar along with total cholesterol, LDL 
and triglyceride levels.  However, it was noted that cinnamon consumption does effect 
the HbA1c in diabetic patients (Allen et al., 2013).  As for now, the active ingredient 
lowering the blood glucose has not been identified.  Hence, the type of cinnamon and in 
which form i.e. powder, capsule, or extract along with the dosage of cinnamon is not yet 
confirmed.   
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Minerals and Management of Type 2 Diabetes   
 Magnesium is one of the essential mineral and is a cofactor for hundreds of 
enzymes as it is involved in several physiologic pathways, including energy production, 
protein synthesis, cell signaling, ion transport, glucose metabolism and many more 
(Harper et al., 2010).  Magnesium deficiency has been associated with developing type 2 
diabetes mellitus due to systemic inflammation and its role in glucose homeostasis and 
insulin action (Saris NE., 2000, Barbagallo M, 2003, Larsson SC.,2007).  Magnesium is 
essential for the activation of phosphate-dependent enzymes in the glycolytic pathway 
and Krebs cycle in the pancreatic β-cells.  It is also essential for the transcription of 
nuclear protein factors for the release of insulin.  It is understood that insulin function is 
magnesium dependent as it activates the β-subunit of tyrosine kinase domain of the 
insulin receptor and stimulates proteins and substrates in the insulin-signaling cascade 
(Harpers, 2010, Sales et al., 2010).  From animal studies it has been observed that insulin 
secretion and action is impaired if there is magnesium deficiency in the body (Suarez A 
et al., 1995, Balon TW et al.,1995).  By supplementing magnesium, the incidence of type 
2 diabetes decreased in animal studies.  However, this has not completely braced in the 
human studies.  It has not been fully supported to show that magnesium supplementation 
benefits the effect on glucose metabolism, insulin action and/or insulin sensitivity.  
However, cohort studies have shown an inverse association between 100 mg per day of 
magnesium supplement and developing risk of type 2 diabetes by 15% (Larsson 
SC.,2007).  In a study, conducted by Sales CH et al. (2011) on 51 type 2 diabetic patients, 
it was observed that magnesium status was altered in them (Sales CH, 2010).  In a meta-
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analysis study of 13 observational studies it was found that higher magnesium intake was 
associated with a lower risk of diabetes (Dong JY et al., 2011).  As it has been understood 
that pancreatic β-cells regulate insulin secretion and glucose tolerance and if there is 
magnesium deficiency then the insulin sensitivity can decrease.  In a randomized, double-
blinded, placebo-controlled study, 97 healthy, non-diabetic participants with 
hypomagnesemia were studied.  When 638 mg of magnesium solution were administered 
for three months, their fasting blood glucose and insulin levels decreased.  This shows 
that pancreatic β-cell function was improved with the ingestion of magnesium (Romero 
F., et al, 2011).  In another study by Mooren FC and colleagues, it was observed that 
when 365 mg per day of magnesium supplement from magnesium aspartate 
hydrochloride was given for six months in 47 overweight individuals their insulin 
resistance was decreased (Mooren FC, et al., 2011).  Thus, this suggests that magnesium 
supplementation may have some effect that can help in preventing type 2 diabetes by 
decreasing insulin secretion.  In addition, it also shows that when type 2 diabetic patients 
who are deficient in magnesium, supplementing them the dosage of magnesium 100 mg 
per day capsules along with regular diabetic medications may help in controlling blood 
glucose levels.   
 Chromium is an important trace element in the body and has been proposed to be 
the cofactor for enhancing the effects of insulin on target tissues. It is an essential nutrient 
that takes place in lipid and carbohydrate metabolism (Anderson RA., 1997).  
Chromodulin has been postulated to have an enhancing cascade effect in the process of 
insulin binding to extracellular α-subunit of the insulin receptors.  In type 2 diabetes 
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patients, there is a high loss of urinary chromium when compared with healthy 
individuals (Morris BW et al.,1999).   Anderson RA and colleagues showed that 
chromium supplementation might be beneficial in the treatment of type 2 diabetes as it 
reduced insulin concentration compared to placebo in the study.  In this randomized 
study, one hundred and eighty type 2 diabetic patients were given chromium supplements 
in the form of chromium picolinate at 100 mcg per day or 500 mcg twice per day for four 
months.  It was observed that HbA1c levels improved significantly in the group taking 
100 mcg chromium per day.  Fasting blood glucose levels were also decreased after four 
months of the supplementation.  There was a significant decrease in fasting and 2-hour 
insulin values in both the groups receiving 100 mcg per or 500 mcg per day of chromium 
supplementation.  In a meta-analysis of placebo-controlled studies it was concluded that 
by 250 mcg per day of chromium supplements for at least three months, fasting glucose 
concentrations can be reduced.  However, in this analysis of seven studies, there was no 
difference in the HbA1c levels in the diabetic patients (Abdollahi M et al. 2013).  Hence, 
even though chromium is an essential element in the carbohydrate metabolism, studies 
have not concretely suggested that chromium supplementation can help as an adjuvant 
therapy or as a preventative therapy in type 2 diabetes.  In addition, chromium has a low 
bioavailability than of dietary chromium, hence taking it in a large quantity may not be 
safe for a long-term use (Food and Nutrition Board, 2001). Thus, more studies with 
different doses of chromium are required to observe the beneficial effects of 
supplementation in the treatment and prevention of type 2 diabetes.      
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Turmeric as an Adjuvant Therapy in Type 2 Diabetes 
 Studies have now concluded that turmeric as well as curcuminoids can help with 
type 2 diabetic mellitus by either lowering blood glucose or increasing insulin sensitivity.     
Selvi and colleagues (2015) used turmeric along with Metformin® in type 2 diabetic 
patients to see the beneficial effect of medication as well as turmeric.  For this study, 
sixty type 2 diabetic subjects who were on metformin therapy were selected.  The study 
was conducted as a randomized trial in which there were two groups of thirty subjects 
each.  As a treatment plan, one group just got 500 mg of metformin therapy twice a day, 
whereas another group received 500 mg metformin therapy twice a day as well as 2 
grams of turmeric supplementation for 4 weeks.  The turmeric capsules were ingested 
after two of metformin administration.  In order to measure the blood sample overnight 
fasting blood was recorded at the beginning of the study, and after four weeks of study.  
From the lab data’s it was observed that subjects who took turmeric supplements along 
with regular metformin therapy, fasting blood glucose was significantly lowered by 15% 
when compared with only metformin therapy which was only of 6%.  In this study, no 
statistically significant difference was measured in the post prandial glucose.  However, 
HbA1C was observed by 5% in the people who took turmeric supplementation.  In 
addition, when oxidative stress was measured turmeric supplementation showed an 
increase in glutathione levels more than just metformin therapy.  This showed that 
turmeric has an antioxidant property when total antioxidant capacity was measured and 
compared with only metformin patients.   In addition to this study results it also showed 
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decrease in lipid levels especially LDL cholesterol levels in patients who took the 
turmeric supplementation.  (Selvi 2015).   
Conclusion: 
The above researches has provided the scientific basics for turmeric and curcumin 
in the role of prevention and treatment for diabetes as well as other diseases. There are 
several mechanisms that have been proposed by which curcumin may exert its effect on 
blood glucose and insulin regulation in rats.  However, more research is required to find 
the exact mechanism of action.   It has been observed that curcumin can help in insulin 
resistance, hyperglycemia, hyperlipidemia and other related disease factors in humans.  
From the analyzed mechanism by Ponnusamy and colleagues it shows a good promising 
outcome for the treatment of type 2 diabetes, which regulates starch digestion in the 
body.  Hence, it is important to differentiate the possible different process that turmeric 
has in order to show the effect on glucose regulation.   
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CHAPTER 3 
 
METHODODLOGY  
 
Participants 
Participants were recruited from Arizona State University, downtown campus and 
nearby community.  Verbal announcements, electronic messages, and posted flyers were 
used to enroll participants for the study.  In order to confirm the number of participants 
that should be used for the study, power analysis calculations were completed (Appendix 
A).  Eight healthy subjects: eight female participated in this study.  All subjects met 
enrollment criteria for age (21-75 years (mean: 25±11y) and body mass index (BMI) ≥ 25 
kg/m 2 (mean 24.7±2.5. kg/m2).  This study included healthy, maintain stable weight for 
past three months (+/- 3 kg; mean:68.7± 8.9kg), non-vegan, non-vegetarian, and 
nonsmoking men and women.   In addition, patients who are not diagnosed with any 
irritable bowel, celiac disease, gall bladder disease, history of kidney stones and have not 
done any medical procedures related to gastrointestinal tract were included. It was made 
sure that women participants are not pregnant or have not become recently pregnant 
and/or are lactating.  All participants showed willingness to follow the screening process 
that includes height, weight, waist circumference, and BMI will be measurement.  They 
followed the 2-hour study protocol that includes eating mashed potato test meals, 
drinking 8 oz. juice (4 oz. orange and 4 oz. beet juice) during their first initial visit of 
screening.  All participants were screened for their willingness to ingest test meals, 
provide blood samples and participate in anthropometric data collection.  from finger 
pricks and plasms insulin were collected to measure blood glucose and insulin levels.  
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Written informed consent (Appendix B) and a medical questionnaire were completed by 
each subject prior to the commencement of the study.  The Arizona State University 
Institutional Review Board, Human Subject Committee approved this research prior to 
initiation of recruitment.  
 
Study Design  
The study followed a randomized, double-blind, crossover design.  It comprised 
of two distinct parts.  The study was conducted for a 9-week period.   
Part I:  conducted during the weeks of 1-3 during which participants consumed a bagel 
the night before coming to the testing center.  They reported to the site in a 12 hour 
fasting state and received a test meal (mashed potato + 8 oz. of orange and beet juice) 
with 500 mg turmeric or placebo of corn meal.  (See Tables 1 for details regarding test 
meals composition, Appendix D test meal ingredients and Appendix E for test meal 
recipe).  500 mg of treatment or placebo capsules were given to the participants to take 
home and were instructed to take one supplement once a day with meal.   
Part II: this part was during the weeks of 4-6weeks where participants were under the 
washout phase.  No medication or placebo treatment were given to participants to 
generate participants’ baseline data.  
Part III:  conducted during the weeks of 7-9, by utilizing a randomized cross-over design.  
This time the participants who received the turmeric treatment plan received the placebo 
and who received the placebo got treatment plan.  Participants were instructed to 
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consume a bagel the night before coming to the testing center.  They reported to the site 
in a 12 hour fasting state and received a test meal (mashed potato) with 8 oz. of orange 
and beet juice mixed with 500 mg turmeric or with placebo of plain orange and beet 
juice.  (Table 3 provides the detail of participants’ randomization using a coin; T = tail 
treatment (turmeric), H = head  placebo; all participants were assigned a number from 
1-15).  
 
Table 1.  Participants treatment randomization.  
Randomization  
Participant # 2 4 6 8 9 10 11 13 
Phase I 
(week 1-3) 
T  T  H H H T  T  H 
Phase III 
(week 10-12) 
H  H  T T T H  H  T 
T = tail  treatment 
H = head placebo 
N = 8 
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Table 2. Test meals composition for mashed potato and orange + beet juice  
  
Weight 
 
Calories 
 
Carbohydrate 
 
 
 
Fat 
 
Protein 
Mashed 
Potato:  
Russet Potatoes1 
 
100 grams  
 
79 kcal 
 
73 kcal 
 
0.7 kcal 
 
5.9 kcal 
      Butter  50 214 kcal 0.07 kcal 213.2 kcal 1.02 kcal 
      Cream 50 173 kcal 167 kcal 9.23 kcal 5.58 kcal 
     Salt  ¼ teaspoon 0 0 0 0 
     Pepper ¼ teaspoon 0 0 0 0 
Juice      
     Orange juice 4 oz. 55 kcal 52 kcal  117 kcal 52 kcal 
     Beet juice  4 oz.  40 kcal 40 kcal 90 kcal 40 kcal 
TOTAL ---- 561 kcal 332.07 kcal 430.13 kcal 104.5 kcal 
Data collected using skipthepie.org 
The Food Processor, ESHA Research Version 12.11 
 
On each day prior to every data collection, participants were instructed to 
consume dinner that can include chicken, fish, turkey or eggs with bread and/or rice 
along with the provided bagel.  Participants were asked to brush and floss their teeth 
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thoroughly the night before the test and the morning of the test.  In addition, they were 
asked to consume dinner no later than 12 hours before the testing.  Participants were 
refrained from any heavy exercise prior to the testing day.   No other food with the 
exception of water was consumed after this dinner meal and participants were in an 
overnight fasting state until they arrived at the research center ABC building, ASU 
Downtown Phoenix Campus the next morning.   
Upon arrival, a fasting blood sample were collected to determine both the fasting 
serum glucose and insulin values for each participant.  During the weeks1-3, participants 
consumed the test meal of mashed potatoes and juice along with either turmeric or with 
placebo.   
Once the participant took the first bite of test meal, time was marked as 0 and was 
considered as a starting point for the 2-hour test.  Participants did not consume anything 
during this time besides water.  They did not move, but were allowed to read or work on 
their computer.  After thirty minutes of testing meal, a finger prick was performed using 
ACCU-CHEK Aviva Plus glucometer 2 (LifeScan Inc., Milipitas, CA).  The same 
glucometer was used throughout the study.  Thereafter, blood draws were performed and 
drawn at 30, 60, 90, and 120 minutes after test meal consumption.  At 0 min and 30 min 
plasma blood samples were collected to measure the insulin.  This data collection 
procedure was repeated for each participant for total of six weeks.  The test meal, juice 
and turmeric were administered by the participants themselves.    
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 After the completion of the test meal and data blood collection, participants then 
left the test site and were free to resume their normal activities along with their dietary 
behaviors.  Subjects were given turmeric or placebo supplements to take for the next 
three weeks.  They were instructed to take the supplement with their first meal.     
 
Food Analysis  
 Food items to make mashed potato and orange juice and beet juice were 
purchased from Safeway grocery store. In addition, turmeric was purchased in a powder 
form from Whole Food grocery store.  The dose of the turmeric that was used in this 
study is based on the amounts previously used in a similar study design.   
 
Anthropometric Measurements 
 Body weight, height and weight circumference measurements were obtained for 
each subject at each of the screening visits.  Body weight and height were measured with 
a calibrated scale (Tanita Tbf 310 Professional body weight Scale), with the subject 
wearing light clothes and no shoes.   BMI was calculated as kg/m2.  Waist circumference 
was measured at the level of the umbilicus, by using a spring adjusted Gulick II 
measuring tape (Country Tech. Inc., Gays Mills, WI) and is reported in inches.   
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Blood Analyses 
 Blood draws for serum glucose were obtained from each participant at: fasting, 
and then at 30, 60, 90, and 120 minutes’ time interval after the test meal with juice and 
turmeric or placebo.  In addition, one capillary glucose measurement was also obtained at 
zero and 180th minute.  A calibrated ACCU-CHEK Aviva Plus glucometer (LifeScan Inc., 
Milipitas, CA) was used to measure capillary glucose values.  A trained phlebotomist and 
RN performed all the blood draws throughout the study.   
 
Statistical Analyses 
Statistical analyses of the results were computed using the Statistical Package of 
Social Sciences (SPSS) version 23.0 by SPSS Inc. (Chicago, IL). Statistically significant 
repeated measure ANOVA was used to find out the significance between the two groups.  
The level of significance will be set up to p≤ 0.05.  Normality for area under the curve 
(iAUC), insulin and HOMA-IR was measured.  Data was normally distributed based on 
Shapiro-Wilk test (p >0.05) for all of the groups. Means and standard error (SE) are 
reported for each variable analyze. 
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CHAPTER 4 
 
RESULTS 
 
Descriptive Characteristics  
 
 
 Twenty-nine participants responded to the online survey for this study that 
examined the effect of turmeric on postprandial glucose and insulinemia in normal 
healthy participants.  Among them, nineteen qualified for the initial online screening.  
Eleven participants (11 females) were consented for the study, where one did not qualify 
for the study and one had transportation conflict.  Thus, nine participants (9 females) took 
part in this study.  Randomization of the participants was done by flipping the coin, T= 
treatment (turmeric) and H= placebo by the volunteers helping with the study.  Since, this 
was a cross-over study design, five participants received treatment and four participants 
received placebo for their visit 2.    After the washout period of 5 weeks, participants who 
received treatment were given placebo and who received placebo were given treatment.    
Data were collected for all 5 visits from all nine participants with the exception of visit 4 
and 5, during which participant #3 was not able to participant due to her gluten sensitivity 
issue.  Therefore, due to the absence of participant #3 data, n=8.  Table 1 shows the 
baseline characteristics of the study participants.   
 
 
 
 
 43 
 
Table 3.   Descriptive characteristics of participants measuring the effect of turmeric1  
 N Minimum Maximum Mean Std. Deviation 
Age 8 18.0 45.0 24.8 10.6 
Weight, kg 8 51.5 81.8 68.7 8.9 
Height, cm 8 155.0 179.0 166.8 8.0 
BMI, kg/m2 8 21.4 27.8 24.7 2.5 
Fat, per 7 15.3 38.4 30.8 8.0 
Average fasting 
glucose (um/mL) 
8 9.26 20.5 15.4 4.3 
Average fasting 
insulin 
8 9.3 20.5 15.4 4.3 
1Average mean for cross over 
 
Postprandial Blood Glucose Response 
Blood glucose was collected during the meal testing via finger prick.  Figure 1 
shows the blood glucose response for 0-, 30-, 60-, 90-, and 120 minutes after treatment 
administration.  Using the repeated measure ANOVA analysis, no statistically significant 
difference in postprandial glycemia between groups was noted (p=0.835; effect size 
0.278) (Table 2 and Figure 1).  Incremental area-under-the-curve (iAUC) for fasting 
glucose were calculated using the trapezoidal rule and there were no statistical significant 
differences for the iAUC glucose response between the turmeric treatment and placebo 
group (p=0.564; effect size 0.050).  However, there was a 4.4% reduction in fasting 
glucose after ingesting turmeric treatment for 3 weeks.  The effect size was large, 0.165.  
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Hence, there may be some physiologically relevance of this change; however, this 
difference was not statistically significant (p=0.278).  Figure 2 shows the blood glucose 
comparison between week 0 and week 3 among the treatment and placebo group.   
 
 
Figure 1 - Postprandial blood glucose concentrations during 120 minutes of the blood 
glucose test, after test meal consumption under treatment and placebo conditions.  Values 
are means ± SD. 
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Figure 2 - Fasting blood glucose concentration comparison between treatment and 
placebo, during week 0 before treatment and week 3 after treatment.  Values are means ± 
SD 
 
 
Table 4:  Fingersticks data for postprandial glucose response for 120 minutes and 3 week 
fasting glucose following test meal consumption in healthy adult participants1,2,3.   
 
 
Postprandial fingersticks (mg/dl) 
1 Data are mean ± SD  
2 P values represent repeated measures ANOVA  
3 N= 8 
 
  
Placebo 
 
 
Treatment 
 
p-value 
 
Effect size 
0 minutes 88.00±7.5 88.25±6.1   
30 minutes 124.50±19.4 121.75±13.8   
60 minutes 110.75±19.3 109.88±13.1   
90 minutes 99.88±9.2 97.00±10.8   
120 minutes 87.50±5.5 88.88±8.9 0.835 0.278 
iAUC 70.86±39.5 64.19±20.2 0.564 0.050 
3-week 
glucose 
87.88±7.9 84.00±5.8 0.278 0.165 
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Plasma Insulin Response 
Plasma insulin was evaluated at baseline (fasting) and 30 min post-test meal 
consumption.  No significant differences were observed for insulin response between 
groups following consumption of test meal (p=0.524; effect size = 0.060) and placebo 
(Figure 3).  Repeated measures ANOVA was conducted to compare the fasting insulin 
concentrations before and after 3 week of treatment administration by group.  It was 
noted that the data were not statistically significant (p=0.814; effect size = 0.008) (Figure 
4).    
Insulin sensitivity were measured by calculating Homeostatic Model Assessment 
of Insulin Resistance (HOMA -IR).  Baseline and 3-week HOMA-IR scores were 
compared.  It was noted that there is no significant difference between the two data sets 
and are not statistically significant (p=0.649) with a small effect size (0.031) (Table 3).   
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Figure 3 - Plasma insulin comparison between fasting and 30 min postprandial insulin 
levels after test-meal consumption for treatment and placebo groups.  Values are means 
± SD 
 
 
 
Figure 4 - Fasting plasma insulin concentration comparison between treatment and 
placebo, during week 0 before treatment and week 3 after treatment.  Values are means ± 
SD 
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Table 5:  Plasma insulin data for 0 min and 3 weeks in healthy adult participants1,2.   
 
 
Plasma insulin (Um/ml) 
1 Data are mean ± SD   
2P values represent repeated measures ANOVA 
 
 
 
Table 6:  HOMA-IR scores for baseline (0 min) and 3 weeks for treatment and placebo 
groups of healthy adult participants1,2,3.   
 
 
HOMA-IR Scores  
1Data are mean ± SD  
2P value represent repeated measures ANOVA vs baseline values 
3 HOMA-IR = Homeostatic Model Assessment of Insulin Resistance 
 
 
 
 
 
 
   
Placebo 
 
 
Treatment 
 
p-value 
 
Effect size 
0 minutes 16.3±5.5 14.6±4.6   
30 minutes 100.9±42.8 85.8±53.9 0.524 0.060 
3-week insulin 15.3±6.4 16.1±5.9 0.814 0.008 
  
Placebo 
 
 
Treatment 
 
p-value 
 
Effect size 
Baseline 3.56±1.35 3.15±0.94   
3-week insulin 3.33±1.40 3.33±1.19 0.649 0.031 
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CHAPTER 5 
DISCUSSION 
 Animal studies have shown that curcumin has a controlling effect on blood 
glucose (Zang, 2013).  Our study looked at the consumption of turmeric, which consists 
of an active ingredient curcumin, in healthy adults which failed to show a decrease in 
postprandial glucose and insulin levels.  This results in our study could be due to small n, 
resulting in deficient power to detect significance.  It may also be possible that 
participants did not comply with data protocols (exercise and consumption of control 
meal prior to data collection, missing the dose of treatment capsules over the 3-week 
period).  Similar to the study done by Wickenburg and colleagues, there were no 
significant difference noted in blood glucose between placebo and treatment group 
(p=0.564).  Karpaga et al. also noted in their study that there is no statistically significant 
difference in post prandial glucose levels, when compared within and between the 
turmeric and placebo groups in type 2 DM patients.  No significant changes were noted in 
postprandial insulin response in our study between the treatment and placebo group 
(p=0.524, effect size 0.060).  This may reflect the controlling levels of glucose and 
insulin respectively.  Conversely, in the study done by Wickenburg and colleagues 
(Wickenburg et al.  2010) serum insulin levels increased after the ingestion of turmeric.  
Hence, this change in our study shows that turmeric may have an effect on insulin 
secretion.  Our study failed to show a significant difference in insulin levels as it may be 
possible that the dosage of treatment was lower than the previous study i.e. 0.05 grams 
versus 6.0 grams respectively.  
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Comparison of fasting blood glucose in three-week data between turmeric and 
placebo was also not statistically significant (p=0.278) but showed to have a large effect 
size (0.165) in our study.  This suggests that there may be some physiological relevance 
with the treatment group.  Unlike participants with type 2 DM taking Metformin®, 
administering turmeric powder in supplement form for 4 weeks showed significant 
reduction in fasting plasma blood glucose when compared with placebo (Karpaga et al. 
2015).   The reduction was noted of 15% for turmeric supplementation group and 6% for 
non-turmeric (placebo) supplementation group.  This shows that turmeric consumption 
has a long term effect and not acute effect on blood glucose levels.  No significant change 
was noted when comparing baseline insulin levels with 3-week insulin levels in turmeric 
administered participants.  Karpaga et al. also noted in their study that turmeric had no 
significant difference in the fasting plasma insulin.  The effect size for 3week insulin was 
small (0.008) in our study.  Hence, this shows that there is no change in insulin levels 
with long term consumption of turmeric.     
In order to asses β-cell function and insulin resistance (IR) from fasting blood 
glucose and insulin, HOMA-IR for baseline and 3 weeks were compared in our study.  
This showed no statistical difference between the turmeric and placebo group (p=0.649) 
with a small effect size (effect size = 0.03).  Similar results were observed in Karpaga and 
colleagues study when 2 g of turmeric was administered in the treatment group along 
with Metformin® and were compared with Metformin® alone.    
Sharma et al. reported in a review article that on average 1.5 g/person/day 
turmeric is consumed on a daily basis in Asian countries and communities like in India 
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(Sharma 2005).  Hence, when comparing the dosage of our study and other studies 
ranging from 400 mg to 6000 mg it suggests that in order to see better outcome from 
turmeric consumption, high amount of turmeric should be administered.  In research, 
curcuminoids, an active ingredient of turmeric contains between 2 to 8% of curcumin 
(Tayyem 2006, Estbeyoglu 2012, Karpaga 2015).  It has shown to have anti-
inflammatory, antioxidant, and hypolipidemic activities along with anti-bacterial, anti-
viral as well as anti-cancer properties.  Curcumin content of turmeric was measured in a 
study by Tayyem and colleges (2005).  Samples of turmeric and curry powder of several 
brands were compared and it was noted that pure turmeric powder had the highest 
curcumin concentration, averaging 3.14% by weight (Tayyem, 2006).  In turmeric 
powders, the average curcumin content (% of the dry weight), was 1.51%, ranging from 
0.58% to 3.14% showing a 5.4-fold difference (Tayyem, 2006).  Hence, when turmeric is 
ingested as a treatment, its active ingredient curcumin varies and it may not be able to 
have the same anticipated effect.    
Turmeric, a yellow colored spice containing curcuminoids has been studied over 
the years.  Most of the research is done on curcumin, an active ingredient of turmeric 
containing between 2 to 5% of the spice.  Commercial available brand of turmeric 
capsules contains turmeric as well concentrated form of curcuminoids.  Dosage varies 
from 500 mg to 1000 mg containing various constituent of curcuminoids that should have 
at least 95% of curcumin to offer therapeutic benefits.  If turmeric is taken in the form of 
spice for treatment, then it should be taken in a sufficient amount to get the active 
ingredient curcumin.  However, it is difficult to increase the turmeric powder 
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consumption due to its earthy taste and low bioavailability.  In our study, 500 mg of 
turmeric ingestion did not show a significant change in the blood glucose and insulin 
levels.  One of the reasons this could be is due to the variability of curcumin in the 
turmeric powder.   By calculating the curcumin content in 500 mg of turmeric assuming 
that it contains 3% of curcumin, our turmeric powder supplement had 15 mg of curcumin.  
Thus, it is essential to know the curcumin content in turmeric powder to more accurately 
assess the content of the active ingredient in order to enhance the possible beneficiary 
health effects (Tayyem, 2006).  Hence, our turmeric powder was lower in curcumin 
content when compared with commercial brand curcumin supplements.  This shows that 
if one is recommended to take turmeric as an adjuvant therapy, curcumin 
supplementation with active ingredients of curcuminoids will be more beneficiary.   
Bioavailability of turmeric curcuminoids is very low, especially if ingested orally 
(Estabeyoglu, 2012).  Various animal and human studies have identified the absorption 
rate of curcumin.  It has been noted that small intestine has a very low absorption rate, yet 
with the highest concentration and liver has a very fast metabolism of curcumin 
(Washlstrom B, 1978, Shoba G, 1998, Estabeyoglu, 2012).  This can explain our study 
result showing no significant change in postprandial blood glucose levels.  In the study 
done by Washlstrom and colleagues in Dawley rats, it was noted that after the oral 
administration of curcumin, most of the curcumin is eliminated through the feces, which 
was unchanged.  (Washlstrom B, 1978. Estabeyoglu, 2012).  It has also been noted in 
studies that human plasma shows high doses of curcumin content after 1 to 2 hour of 
ingestion (Shoba G, 1998, Sharma R.A., 2001, Lao C.D., 2006, Vareed S.K., 2008, 
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Estabeyoglu, 2012).  This suggests that, high dose of curcumin is better for treatment due 
to its reduced amount of solubility.  In Indian cuisines, turmeric is consumed in daily as a 
cooking spice.  It is added in most of the lentils soups, cooked vegetables, rice, and 
sometimes in various kinds of breads.  There are also other spices mixed into the food, 
but turmeric is considered on the more important spices when during preparation. 
Turmeric is added as one of the spices to prepare food items.  There are other spices 
mixed into the food along with turmeric.  In order to increase turmeric bioavailability in 
the body, various methods have been studied.  Piperine an active component in pepper 
has been found to increase turmeric bioavailability by two folds (Arcaro 2014).  Hence, 
adding black pepper along with turmeric can help in bioavailability.   Oil or some kind of 
fat is usually present in these cooked food items.  Thus, due to the lipophilic property of 
turmeric, adding fat like coconut oil, corn oil, olive oil etc. in the dish may help in 
increasing the absorption of the active ingredient curcumin.   
Turmeric bioavailability can be enhanced with heat (Kurein, Singh, Matsumoto, 
Scofield, 2007).  Kurein and colleagues study demonstrates that when heat is given there 
is an increase in the water solubility of turmeric as well curcumin.  It was noted that the 
solubility increased by 12 fold in curcumin and threefold increase in turmeric when it was 
heated for 10 minutes in a boiling water bath at about 90 degrees Celsius.  However, it 
also showed that following the incubation of heated curcumin samples at 4 degrees 
Celsius, stability decreased by 47% and 67% after 12 and 72 hours respectively.  When 
turmeric samples were incubated after heating, its stability decreased by 17% and 25% 
after 12 and 72 hours respectively (Kurein et al).  It was also noted that heat did not alter 
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the molecule structure significantly.  In addition, higher peak was observed in the study 
for one of the components of curcumin, bisdemethoxycurcumin.  The peak of curcumin 
heat treatment stability showed a higher peak in a heated sample than in the non-heated 
sample.  Thus, this shows that heat protects curcumin from breaking down fast.  Hence, if 
we heat the turmeric powder before ingestion, it may help in increasing the solubility in 
the body.    
Our test meal contained Russet mashed potatoes made from cream, milk, butter, 
salt and pepper.  Ponnusamy et al. suggested in their study that one of active ingredient of 
turmeric bisdemethoxycurcumin (BDMC) acts as a human pancreatic -amylase (HPA) 
inhibitor. 10% BDMC was present in the sample and it was noted to hydrolyze the starch, 
working as a small molecule HPA inhibitor (Ponnusamy et al. 2012).  This effect was not 
observed in our current study statistically, however postprandial blood glucose levels 
decreased with a small effect size and insulin with a medium effect size.  This could 
support the Ponnusamy et al. in vitro study that BDMC may have acted as HPA inhibitor 
during the test meal time period that consists of Russet mashed potato, high in starch 
content. In addition, as there was butter and pepper added to the recipe, bioavailability of 
turmeric might have increased to give a small and medium effect size on the postprandial 
glucose and insulin response respectively.     
Sharma and colleagues reported that more than 2,400 metric tons of turmeric is 
imported into United States yearly (Sharma RA, 2005, Tayyem, 2006).  This shows that it 
will be beneficial to know the amount of curcumin consumed in form of turmeric as a 
spice to observe the biological effects.    
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In conclusion, our study did not support our hypothesis.  Turmeric consumption 
did not significantly reduce post prandial blood glucose levels when turmeric was 
ingested.  This may be due to glucose levels been strictly regulated in glucose tolerant 
healthy participants.  When three-week turmeric consumption results were analyzed it did 
not show any significant change in blood glucose levels, however; it did appear to 
attenuate when compared with placebo with a smaller effect size. Our study failed to 
show any significant change in fasting plasma insulin levels when compared with placebo 
after three weeks of turmeric supplementation.  However, it did show a larger effect size 
suggesting that long term consumption of turmeric may have some positive effect in 
insulin levels.  Thus, it was observed that turmeric consumption has more of a long term 
effect than of an acute, short term effect.  More studies are needed to measure the long 
term administration of turmeric and its effect on blood glucose and insulin levels.  If this 
crossover study is repeated, recruiting 25 to 30 participants will give 80 percent 
probability measuring a treatment difference change of 3.8 units.  Future research is 
essential to examine the turmeric powder supplement benefits over a long period of time 
in blood glucose and plasma insulin levels in healthy adults.  This may help in preventing 
the occurrence of type 2 diabetes.   
Furthermore, studies may want to evaluate the administration of turmeric to 
subjects with more abnormal parameters such as insulin resistant, impaired glucose 
tolerant or prediabetes.  In addition, turmeric supplementation along with some kind of 
fat and warm food should be experiment to observe the solubility.  More research is 
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required to determine the mechanism that may be involved in possibly increasing insulin 
levels with the provision of turmeric.   
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SAMPLE SIZE CALCULATIONS 
Power calculations were conducted online using the software developed by David 
Schoenfeld with support from the MGH Mallinckrodt General Clinical Research 
JavaScript version developed by REMorse.    
Study by Wickenburg J et al. regarding turmeric ingestion and its effects on 
postprandial on insulin levels was examined.  The minimal detectable difference in 
means was calculated as 254.  Within patient standard deviation was calculated based on 
provided SEM (Standard Error Mean) and sample size n.  This calculation gave 374.  
Hence, with 81% probability that the study will detect a treatment difference in order to 
see a significant change at a two-sided 0.05 significant level in insulin levels at 30 min 
postprandial, a total sample size of 37 patients was calculated.   
Our goal was to recruit 15 participants for this two-treatment cross over study, as 
to follow Wickenburg J et al. study.  However, we were short in achieving that number as 
our sample size for our study was 8.    
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APPROVAL: MODIFICATION 
 
Carol 
Johnston 
SNHP: 
Nutrition 
602/827-
2265 
CAROL.JOHNSTON@asu.edu 
Dear Carol Johnston: 
On 10/28/2015 the ASU IRB reviewed the following protocol: 
 
Type of Review: Modification 
Title: Effects of Curcuma longa (turmeric) on postprandial 
glycemia, blood lipid profile, and bowel transit time. 
Investigator: Carol Johnston 
IRB ID: STUDY00003267 
Funding: Name: Graduate College 
Grant Title: None 
Grant ID: None 
Documents Reviewed: • protocol, Category: IRB Protocol; 
• reference, Category: Technical materials/diagrams; 
• online survey, Category: Recruitment Materials; 
• instructions, Category: Participant materials (specific 
directions for them); 
• bowel activity sheet, Category: Measures (Survey 
questions/Interview questions /interview guides/focus 
group questions); 
• flyer and email text, Category: Recruitment 
Materials; 
• adherence calendar, Category: Measures (Survey 
questions/Interview questions /interview guides/focus 
group questions); 
• consent , Category: Consent Form; 
• health history questionnaire, Category: Screening 
forms; 
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The IRB approved the modification. 
 
 
When consent is appropriate, you must use final, watermarked versions available under 
the “Documents” tab in ERA-IRB. 
 
In conducting this protocol you are required to follow the requirements listed in the 
INVESTIGATOR MANUAL (HRP-103). 
 
Sincerely, 
 
 
IRB Administrator
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EFFECTS OF HERBAL SUPPLEMENT ON POSTPRANDIAL GLYCEMIA, 
 
INTRODUCTON 
BLOOD CHOLESTEROL AND BOWEL TRANSIT TIME 
 
The purposes of this form are (1) to provide you with information that may affect your 
decision as to whether or not to participate in this research study, and (2) to record your 
consent if you choose to be involved in this study. 
 
RESEARCHERS 
Dr. Carol Johnston, a Nutrition professor at Arizona State University Downtown 
Campus has requested your participation in a research study. 
 
STUDY PURPOSE 
The purpose of the research is to examine the effects of a common herb for improving 
common health parameters including blood glucose and cholesterol concentrations and 
bowel regularity. 
 
DESCRIPTION OF RESEARCH STUDY 
You have indicated to us that you are 18 years of age or older, a non-smoker and 
healthy but experience some degree of bowel irregularity. Participants will be asked 
to maintain their usual diet and physical activity level throughout the trial with the 
exception of the day prior to meal testing. This study will initially involve the 
completion of a brief health history questionnaire to demonstrate the absence of 
medical conditions that may impact the study. Your weight, height, and girth will be 
measured at this time. This first meeting will take about 15 minutes. There are four 
additional visits: 2 meal test visits that will last about 2 hours and 2 short visits 
scheduled three weeks after meal testing. The procedures on meal test days are 
identical. On the day prior to meal testing you are asked to avoid heavy exercise 
(normal activities such as walking to work or walking the dog is ok). You will be asked 
to eat a normal breakfast and lunch of your choice. For the evening meal, we will ask 
you to eat chicken, turkey, fish, or eggs with bread or rice. We will also provide a 
bagel for you to eat with this meal. Following dinner, you will fast overnight and not 
consume any food or beverage with the exception of water. Participants will be 
asked to brush teeth thoroughly the night before the test and the morning of the test 
and to floss between teeth thoroughly the night before the test and the morning of 
the test. The following morning, you will travel to ASU (the Nutrition labs at the 
ABC1 Building on the ASU Downtown campus) early in the morning. We will collect 
a blood sample from a vein, and your finger will be pricked for another blood 
sample. You will sit down and consume a test meal (mashed potatoes and juice). 
Your finger will be pricked four more times over the next 2 hours. You may drink 
water during these two hours but you are not to consume any food and you cannot lie 
down. We will collect another blood sample from a vein at 30 minutes postmeal, and 
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we will ask you to breath into a valve prior to eating the test meal and at 60 and 120 
minutes postmeal. During this 2-hour test period, you may read, study, or work on 
the computer at the test site. Once testing is complete, you may proceed with your 
normal activities. You will be provided with capsules to take daily for the next 3 
weeks. We will also ask you to complete a daily report to assess bowel function. At 
the end of the 3 weeks, we ask you to return to the test site in a fasted state to provide 
a venous blood sample, a single breath test, and a single finger prick, and to turn in 
your bowel activity sheets. This entire process will be repeated after a 5 to 6-week 
interval. 
 
Blood sampling and finger pricks will be conducted under sterile conditions using 
disposable, retractable lancets, and the level of glucose and cholesterol in blood will be 
recorded. Your breath will be analyzed for hydrogen. 
 
RISKS 
Bruising of the skin or a feeling of faintness is possible during the finger pricks and 
blood draws. Disposable retractable lancets will be used and sterile conditions will be 
used. The herbal supplement being tested is commonly used around the world and no 
adverse effects are anticipated. However, if any stomach or intestinal concern develops 
during the study, such as diarrhea or constipation, please contact the investigators. 
 
BENEFITS 
There is no direct benefit for participating in this trial. If desired, you will be provided 
with study results and your personal blood data at the end of the study. 
 
NEW INFORMATION                                                                                                       
If the researchers find new information during the study that would reasonably change 
your decision about participating, then they will provide this information to you.  
 
CONFIDENTIALITY 
All information obtained in this study is strictly confidential unless disclosure is 
required by law. The results of this research study may be used in reports, 
presentations, and publications, but your name or identity will not be revealed. In 
order to maintain confidentiality of your records, Dr. Johnston will use subject codes 
on all data collected, maintain a master list separate and secure from all data 
collected, and limit access to all confidential information to the study investigators.  
 
WITHDRAWAL PRIVILEGE 
You may withdraw from the study at any time for any reason without penalty or 
prejudice toward you. Your decision will not incur negative treatment to you by the 
researchers. 
 
COSTS AND PAYMENTS 
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The all test foods and supplements will be given to you during the study free of charge. 
You will receive four Target cards [one card at visits 2 ($5), 3 ($10), 4 ($15), and 5 ($20)] 
for a total of $50. You may need to pay for parking during your visits. 
 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of your 
legal rights. However, in the event of harm, injury, or illness arising from this study, 
neither Arizona State University nor the researchers are able to give you any money, 
insurance coverage, free medical care, or any compensation for such injury. Major 
injury is not likely but if necessary, a call to 911 will be placed. 
 
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the study, 
before or after your consent, will be answered by Dr. Carol Johnston; 500 N. 3rd Street 
Phoenix, AZ 85004; 602-827-2265. 
If you have questions about your rights as a subject/participant in this research, or if 
you feel you have been placed at risk, you can contact the Chair of the Human Subjects 
Institutional Review Board, through the ASU Research Compliance Office, at 480-
965 6788. 
This form explains the nature, demands, benefits and any risk of the project. By signing 
this form, you agree knowingly to assume any risks involved. Remember, your 
participation is voluntary. You may choose not to participate or to withdraw your 
consent and discontinue participation at any time without penalty or loss of benefit. 
In signing this consent form, you are not waiving any legal claims, rights, or remedies. 
A copy of this consent form will be given to you. 
 
Your signature below indicates that you consent to participate in the above study. 
 
Subject's Signature Printed Name Date __________________________________ 
 
Contact phone number Email __________________________________________ 
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the potential 
benefits, and possible risks associated with participation in this research study, have 
answered any questions that have been raised, and have witnessed the above signature. 
These elements of Informed Consent conform to the Assurance given by Arizona State 
University to the Office for Human Research Protections to protect the rights of human 
subjects. I have provided the subject/participant a copy of this signed consent document." 
Signature of Investigator____________________                    Date _________________              
__________________                                                                 
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Mashed Potato Ingredients  
Serves 1 (~300 grams)  
Ingredients 
•400 g Russet Potatoes, peeled and cut lengthwise into quarters 
•1/4 (1.5 grams) teaspoon salt 
•2 Tbsp (15 grams) heavy cream 
•1 Tbsp (15 g) butter 
•1 Tbsp milk (or more) 
•Salt ¼ teaspoon and Pepper 1/2 teaspoon 
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Mashed Potato Recipe – Method 
1) Start 4 cups of water to boil in a deep saucepan.   
2) Add one teaspoon of salt to the water.  
3)  Place the peeled and cut potatoes into a medium saucepan. Wg: 2721 grams 
4) Turn the heat on to high, and bring the water to a boil. Time: 15 minutes 
5)  Reduce the heat to low to maintain a simmer, and cover. Time: 10 minutes 
6) Cook for 15 to 20 minutes, or until you can easily poke through them with a fork. 
7) While the potatoes are cooking, melt the butter and warm the cream. You can heat 
them together in a pan on the stove or in the microwave. 
Time  Melt the butter 8 Tbs. (113 g) for 30 sec and mix it with cream 160 g 
and warm for 10 seconds microwave 
8) When the potatoes are done, drain the water and place the steaming hot potatoes 
into a large bowl.  
9) Pour the heated cream and melted butter over the potatoes. Mash the potatoes 
with a potato masher.  
Time for mashing potatoes: 45 mashes  
10) Then use a strong wooden spoon (a metal spoon might bend) to beat further. 
Time for beating the potatoes: one-min 
11)  Add milk and *beat until the mashed potatoes are smooth.  
Milk: 112 g Time to beat: ~ 2 min 
*Don't over-beat the potatoes or the mashed potatoes will end up gluey. 
12)  Add salt and pepper to taste. 
